EnGeneIC has commenced it's COVID-19 EDV safety trial in Australia.

While the COVID-19 EDV vaccine is being developed for immune-compromised people we are also currently vaccinating healthy volunteers at sites in Melbourne & Sydney, with Perth soon to follow.
No vaccine to date is directed towards vulnerable patients with compromised immune systems and while much focus is on vaccine rollout, the same at-risk patients may not respond to currently available vaccines.
Although EnGeneIC has developed its EDV nanocell for oncology applications, patients with late-stage cancer in our clinical trials are also the same vulnerable patients. In these cancer trials, dosing with EDVs has resulted in activation and proliferation of white blood cells (WBCs) including CD8+ T cells, macrophages, NK cells, and dendritic cells. The same proven approach has potential in vulnerable COVID-19 patients and indeed in most future viral pandemics for the target population.
Ethics approval has been submitted to progress to a trial for immune-compromised people, particularly in cancer patients, with the aim to help vulnerable people fight COVID-19.